UBS Group
ATHE

UBS Group’s Alterity Therapeutics ATHE Stock Holding History

UBS Group’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,004
Closed -$44.9K – 10233
2025
Q1 		$44.9K Buy
13,004
+12,620
+3,286% +$48.3K ﹤0.01% 7673
2024
Q4 		$1.27K Sell
384
-12,301
-97% -$19.5K ﹤0.01% 9278
2024
Q3 		$16.6K Buy
12,685
+12,683
+634,150% +$18.7K ﹤0.01% 7473
2024
Q2 		$4 Hold
2
– – ﹤0.01% 9401
2024
Q1 		$4 Buy
+2
New +$4 ﹤0.01% 9148
2023
Q4 		– Sell
-127
Closed -$315 – 9285
2023
Q3 		$315 Buy
+127
New +$352 ﹤0.01% 8589
2022
Q2 		– Sell
-1,049
Closed -$9K – 10289
2022
Q1 		$9K Sell
1,049
-311
-23% -$2.58K ﹤0.01% 8529
2021
Q4 		$10K Buy
+1,360
New +$14.8K ﹤0.01% 8756
2021
Q3 		– Sell
-466
Closed -$6K – 9512
2021
Q2 		$6K Buy
466
+459
+6,557% +$6.22K ﹤0.01% 8425
2021
Q1 		$0 Sell
7
-185
-96% -$3.12K ﹤0.01% 8973
2020
Q4 		$3K Buy
192
+168
+700% +$2.65K ﹤0.01% 7982
2020
Q3 		$0 Sell
24
-5,287
-100% -$108K ﹤0.01% 7962
2020
Q2 		$63K Buy
5,311
+5,003
+1,624% +$31.8K ﹤0.01% 5673
2020
Q1 		$2K Buy
308
+301
+4,300% +$2.07K ﹤0.01% 7595
2019
Q4 		$0 Sell
7
-228
-97% -$2.29K ﹤0.01% 8096
2019
Q3 		$3K Sell
235
-399
-63% -$4.43K ﹤0.01% 7617
2019
Q2 		$8K Buy
634
+427
+206% +$6.81K ﹤0.01% 7173
2019
Q1 		$4K Sell
207
-804
-80% -$13.7K ﹤0.01% 7244
2018
Q4 		$13K Buy
1,011
+238
+31% +$4.14K ﹤0.01% 7082
2018
Q3 		$16K Buy
773
+636
+464% +$13.2K ﹤0.01% 6917
2018
Q2 		$3K Sell
137
-471
-77% -$9.35K ﹤0.01% 7617
2018
Q1 		$13K Buy
608
+121
+25% +$3.24K ﹤0.01% 6703
2017
Q4 		$15K Buy
487
+90
+23% +$2.82K ﹤0.01% 6753
2017
Q3 		$11K Buy
397
+359
+945% +$9.76K ﹤0.01% 6819
2017
Q2 		$1K Sell
38
-320
-89% -$7.96K ﹤0.01% 7474
2017
Q1 		$11K Buy
358
+314
+714% +$7.42K ﹤0.01% 6542
2016
Q4 		$1K Sell
44
-475
-92% -$12.7K ﹤0.01% 7602
2016
Q3 		$23K Buy
519
+459
+765% +$22.9K ﹤0.01% 6185
2016
Q2 		$3K Sell
60
-537
-90% -$20.6K ﹤0.01% 7312
2016
Q1 		$17K Buy
597
+219
+58% +$7.31K ﹤0.01% 6310
2015
Q4 		$16K Buy
378
+374
+9,350% +$19K ﹤0.01% 6944
2015
Q3 		$0 Buy
+4
New +$254 ﹤0.01% 8394
2015
Q1 		– Sell
-54
Closed -$6K – 8787
2014
Q4 		$6K Buy
+54
New +$5.84K ﹤0.01% 8801

Other funds holding ATHE

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $3.28B AUM 23.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's ATHE Position: Q2 2025 in Review

UBS Group sold out of Alterity Therapeutics (ATHE) in Q2 2025, closing a stake of 13,004 shares — an estimated $44.9K sold.

UBS Group first reported a position in ATHE in Q4 2014 and held it in 33 quarters. The position peaked at $63K in Q2 2020. 11 funds tracked by Wall St. Rank hold ATHE as of Q2 2025.

  • UBS Group reported no remaining Alterity Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 13,004 Alterity Therapeutics shares in Q2 2025, an estimated $44.9K.
  • UBS Group first reported a position in Alterity Therapeutics in Q4 2014 and held it in 33 quarters.
  • UBS Group's Alterity Therapeutics position peaked at $63K in Q2 2020.
  • 11 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.